Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 1996Clinical Transplantation

Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations*

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMatthew R. FirstUnited States Naval Research LaboratoryTSTimothy SchroederQueen Mary University of LondonAnthony P. MonacoAnthony P. MonacoBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

First et al. (1996) studied this question.

synapsesocial.com/papers/6a8700e4a810ea404bcf9d4bhttps://doi.org/10.1111/j.1399-0012.1996.tb00645.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of area under the curve cyclosporine monitoring in renal transplantation.1993 · 66 citations
  2. 2VARIABLES AFFECTING BIRTHWEIGHT AND GRAFT SURVIVAL IN 197 PREGNANCIES IN CYCLOSPORINE-TREATED FEMALE KIDNEY TRANSPLANT RECIPIENTS1,21995 · 108 citations
  3. 3Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation1993 · 469 citations
  4. 4Predictors of long‐term primary cadaveric renal transplant survival1993 · 70 citations
  5. 5Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability1992 · 122 citations